Zydus Lifesciences Limited

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about its participation in an investor conference, Equirus Annual India Conference 2026, on August 13, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has received an Establishment Inspection Report (EIR) from the USFDA for its injectable facility with a Voluntary Action Indicated (VAI) classification.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about the schedule of its meet for Q1 FY27 post results earning call details. The financial results for Q1 2026-27 will be declared on Tuesday, August 11, 2026, and a post-results Q&A session through webinar has been scheduled on the same day at 4:00 p.m. IST. The details to join the call are provided in the attached file.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has received an order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, regarding the acquisition of assets from Sterling Biotech Limited, a joint venture company. The authority has determined the market value of the transferred property at ₹ 1,542.60 million and ordered recovery of alleged deficient stamp duty of ₹ 53.47 million along with penalties aggregating to ₹ 55.07 million, resulting in a total demand of ₹ 108.54 million.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has temporarily suspended operations at its Ahmedabad facilities due to torrential rain and water logging, but has resumed operations as the weather condition improves.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has received approval for a Phase III trial of Desidustat in patients with Sickle Cell Disease, in collaboration with the Indian Council of Medical Research (ICMR). The trial will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia in sickle cell disease patients.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has responded to a clarification sought by the National Stock Exchange of India Limited regarding a recent news item about a Delhi HC temporary restriction on the supply of its cancer drug Ikra due to an AbbVie patent dispute. The company stated that there are no negotiations or events requiring disclosure under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also claimed that the event is not material in terms of the company's materiality policy and the provisions of the regulations. The company's equity shares did not experience significant trading movement on July 14, 2026, and it believes there is no material impact of this event on the company.

Zydus Lifesciences Limited

The NSE has sought clarification from Zydus Lifesciences Limited regarding a recent news item about a Delhi HC temporary restriction on the supply of their cancer drug Ikra due to an AbbVie patent dispute.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about the newspaper publication of the notice of its 31st Annual General Meeting (AGM). The AGM will be held on August 4, 2026, through video conferencing. Members can cast their votes electronically or through the physical mode. The cut-off date for eligibility to vote is August 4, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026, along with the Integrated Annual Report for the Financial Year ended on March 31, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about a newspaper advertisement published in the Financial Express English and Gujarati Edition with regard to the Notice to the shareholders for claiming their shares which are proposed to be transferred to Investor Education and Protection Fund (IEPF).

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about the publication of a notice and information regarding the 31st Annual General Meeting (AGM) of the company, which will be held on August 11, 2026, through video conferencing. The notice includes details about the Integrated Report for the financial year 2025-26, the manner of registering/updating email addresses, and the procedure for casting votes through e-voting.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about an update on the acquisition of API business from Sterling Biotech Limited. The transaction was initially expected to be completed by December 31, 2024, but was extended to June 30, 2026, and now further extended to September 30, 2026, due to SBL's ongoing completion of certain conditions precedents.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about a joint venture in Sri Lanka, where it will subscribe to 50% of the total paid-up equity share capital of Zydus Sunshine Lifesciences (Private) Limited, a recently incorporated company to set up a manufacturing facility in Sri Lanka.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has announced disclosures under SEBI (Prohibition of Insider Trading) Regulations regarding its recent share buyback program. The announcement details the acceptance of equity shares tendered by promoters, promoter group, directors, and their immediate relatives through a proportionate tender offer. Notably, Zydus Family Trust, a key promoter, had 63,49,542 equity shares accepted in the buyback. Post-buyback, the Trust's holding percentage slightly increased from 74.96% to 74.98%. This signifies strong promoter participation and their continued significant stake in the company following the tender offer.

Zydus Lifesciences Limited

Zydus Lifesciences Limited announced the extinguishment of 8,730,158 fully paid-up equity shares following a share buyback. These shares, with a face value of INR 1 each, were bought back at a price of INR 1,260 per share through a tender offer route. The aggregate amount for this buyback totalled INR 1,100 crore. This action reduces the company's outstanding share capital, which can potentially enhance earnings per share (EPS) and shareholder value for the remaining investors.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has submitted a copy of the post buyback public advertisement pertaining to the buyback of up to 87,30,158 equity shares at INR 1,260 per share for an aggregate amount not exceeding INR 1100,00,00,000.